Pfizer’s Irak-4 inhibitor PF-06650833 definitely, definitely doesn’t work in hidradenitis suppurativa, but there’s at least partly better news for Priovant.
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.